Ranirestat

DB05327InvestigationalSmall molecule

Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used... It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.

Mechanism: Ranirestat alleviates diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This drug has a stronger inhibitory effect and is longer acting compared to other drugs in this therapeutic area. Ranirestat showed good penetration into the nerve tissue, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose in a clinical study.
Curator reviewed
Primary indication: Investigated for use/treatment in neuropathy (diabetic).Curator reviewed
Formula / weight: C₁₇H₁₁BrFN₃O₄ · 420.189 g/mol (avg)
Code names: AS-3201 · SX 3030 · SX 3201

Resolves to

Compound

UNIIZ26P56GFTVCAS147254-64-6ChEMBLCHEMBL334830PubChem153948

Structure

InChIKeyQCVNMNYRNIMDKV-QGZVFWFLSA-NSMILESFC1=C(CN2C(=O)C3=CC=CN3[C@@]3(CC(=O)NC3=O)C2=O)C=CC(Br)=C1

Targets

P15121AKR1B1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ranirestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account